SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " Meta " 2,046 found 🔀 AI-powered Shuffle
Meta delays new business terms after outcry over potential web scraping of news sites
Meta said it was postponing the rollout of new terms for its business accounts after an outcry from media companies and open-web advocates who said the updated rules would allow
Rutgers Is Awarded $3.6 Million to Improve Heart and Metabolic Health in Older Adults With HIV
With a $3.6 million grant from the National Institutes of Health, Rutgers researchers will conduct one of largest and most comprehensive studies of heart and metabolic conditions among older adults living with HIV.
Meta delays new business terms after outcry over potential web scraping of news sites
With the change Meta potentially could build AI services to compete with publishers.
Meta delays new business terms after outcry over potential web scraping of news sites
Meta said it was postponing the rollout of new terms for its business accounts after an outcry from media companies and open-web advocates who said the...
Meta is delaying new business terms that would let it scrape news sites
The U.K. competition regulator opened an investigation into the terms, while Meta says the update is not aimed at news sites
Meta delays new business terms after outcry over potential web scraping of news sites
Meta is delaying new terms for business accounts after a backlash from media companies and open-web advocates
Meta delays new business terms after outcry over potential web scraping of news sites
Meta said it was postponing the rollout of new terms for its business accounts after an outcry from media companies and open-web advocates who said the updated rules would allow
Meta delays new business terms after outcry over potential web scraping of news sites
Meta is delaying new terms for business accounts after a backlash from media companies and open-web advocates. The terms, set for October 30, would allow Meta to...
Michael Wilbon announces leave of absence from ESPN due to ‘multiple health issues’
The longtime co-host of "Pardon The Interruption" put no timetable on his return to the show or other broadcasting with ESPN and ABC.
Ex-Meta security chief: Giving AI agents financial logins is 'insane'
The dynamic has created a dilemma for banks that are now grappling with a growing wave of customer-authorized bot activity, Alex Stamos said.
NASA’s Mission to Study Sunlight Completes Vacuum, Vibration Testing
Bright white lights reflect off the metallic hardware of a satellite poised for inspection. Engineers outfitted with bunny suits traverse the clean room, past
Forbes features manufacturing success story in Hagerstown
Just one year after acquiring a local Hagerstown business, Andrew Kurzrok is celebrating his success with the team that helped him achieve it. For over a decade, Andrew worked for a global manufacturing company and traveled...
4.1-Billion-Year-Old Martian Meteorite Is A "Rosetta Stone" For The Red Planet's Distant, Watery Past
The space rock, recovered from the Sahara Desert in Mali, is easily the oldest igneous rock we know of from Mars.
Modern fitness enthusiasts turn toward advanced metabolic science to reach new heights
Men’s health optimization is evolving as fitness enthusiasts trade quick-fix trends for documented metabolic research and cellular physiological data. You have likely spent years tracking sets, logging miles, and testing diets that promised effortless gains but delivered mixed outcomes. Generic fitness rules often leave active men frustrated because standard gym routines fail to address individual […]
Competition returns, driving up value for quality assets
Meta description: What business owners need to know about M&A in 2027, from private equity investment and deal valuations to industries poised for growth.
Novel e-skin advances personal health monitoring
Innovative nano-engineering uses biocompatible materials to simultaneously monitor cardiac signals and measure sweat metabolites.
Novel e-skin advances personal health monitoring
Innovative nano-engineering uses biocompatible materials to simultaneously monitor cardiac signals and measure sweat metabolites.
Real-World Weight Journeys: Exploring Health Experiences to Improve Care
(Feature Impact) A number on a scale tells only part of the story. Living well is also about having energy, feeling your best and enjoying a good quality of life. Yet each person’s path is different, and lifestyle changes, medicines and other approaches to managing weight can affect health in different ways. TNCMS.AdManager.render({region: 'fixed-big-ad-top-asset', slot: 1, fold: "above"}); No two weight-management journeys look the same. Some people are taking their first steps toward healthier habits. Others are balancing health conditions, caring for family members, coping with stress or exploring new treatment options. Along the way, they may find support that helps them succeed or encounter obstacles that make progress more difficult.These stories provide valuable insights into what it takes to improve health in everyday life.That’s the idea behind the American Heart Association’s Healthy Living BEYOND Weight Study. By learning directly from adults across the country, researchers aim to better understand the challenges, motivations and factors that shape weight and health outcomes over time. The goal is to generate insights that can help improve support, inform care and empower more people to live healthier lives.What Factors Influence WeightNearly 1 in 3 U.S. adults are overweight and 2 in 5 are obese, according to the National Institutes of Health. Weight is shaped by many factors, including:Genetics and hormonesAccess to healthy food, safe places to exercise and healthcareChronic stress and mental healthMedications and metabolismCommunity conditions, as where you live can influence your ability to live a healthy lifeHow Joining a Study Can Make a Difference Led by the American Heart Association, the Healthy Living BEYOND Weight Study is open to U.S. adults with a BMI of 25 or higher, including those who have tried lifestyle changes, weight-management medicines or weight-loss surgery. By sharing information about their health and daily lives, participants can help researchers better understand how to improve care.Interest in newer weight-loss medicines, such as GLP-1s, has grown rapidly. While these treatments are helping many people, researchers are still learning about their long-term effects and how they fit into everyday life. People who currently use or previously used a GLP-1 may be eligible to participate and help generate insights that could improve care for others.Reasons to Join This StudyBy joining this study, participants can help researchers better understand the long-term impact of treatments, identify what helps people succeed and uncover the challenges they face along the way. The information they share can help fill important gaps in research, shape better and more compassionate care and guide future health recommendations.According to the Pew Research Center, 31% of U.S. adults report they’re online “almost constantly.” The study is conducted entirely online, making participation convenient and easy. It can be completed from home on a schedule that works best for each participant.Consider these reasons to participate:Your story matters. By participating, you may help build knowledge that can improve care, guide health recommendations and help people live healthier lives.It’s easy. The study is conducted entirely online, making it simple to join and stay involved at your own pace.It’s safe and respectful. All data is collected with your informed consent, protected by privacy safeguards and handled according to rigorous ethical and scientific standards.You won’t be alone. Millions of people are navigating weight and health challenges. By sharing your journey, you can help researchers better understand what works, what support is needed and how to shape better and more compassionate care for others.Learn more and consider signing up at Heart.org/GoBeyond.Photo courtesy of Shutterstock
Pushing the limits of optics with noise
Bo Xiong uses engineered noise and AI tools to expand the multiplexing capabilities of ultrathin optical structures called metasurfaces.
Legal settlement by Meta regarding mental health harm. Who protects children from social media?
ONG Internacional Bullying Sin Fronteras
BMO Completes Acquisition of Euroz Hartleys Capital Markets Business, Strengthening its Leading Global Metals and Mining Franchise
BMO Financial Group (TSX: BMO) (NYSE: BMO) today announced the completion of its acquisition of the Australian capital markets business of Euroz Hartleys Group Limited (ASX: EZL), strengthening its leading global metals and mining franchise and expanding BMO Capital Markets' presence in Australia.
Meta's AI shopping agent threatens Amazon's lucrative advertising business
Meta’s AI shopping assistant Muse could threaten Amazon’s retail and ad dominance.
Why AI is boosting Meta's ad business while hurting Google search
The gap between Meta's ad revenue growth and Google's search expansion was the widest it's been since 2021 in the latest quarter.
DoorDash sees limited AI orders, but explores new tools
DoorDash CEO Tony Xu discusses AI agents like Meta's Muse, revealing low order numbers but plans for enhancing DoorDash's AI tools.
Heidi Klum reveals Halloween costume as her iconic party marks 25 years
Heidi Klum underwent a bloody transformation to become a giant, gruesome severed hand for Halloween.
Science Notes – Following the lead: the impact of the metal industry in medieval England
While today the health impacts of lead exposure are well documented, in the past its hazards were unknown, a silent killer that had an impact on potentially millions of people…
Scientists Confirm "Spiders Do Sleep" For The First Time, Ancient Egypt’s First Female King Finally Recognized, And Much More This Week
All the biggest science news stories of the week.
Scientists discover metals that defy the deep freeze at -424°F
Scientists have discovered a surprising mechanism that allows certain metals to resist cracking at temperatures as low as -253°C (-424°F), when similar materials typically become dangerously brittle. Instead of breaking, two experimental alloys reorganize their internal structures, creating new ways to absorb stress and remain flexible.
Drake Equation: The "Second Most-Famous Equation In Science" Turns 65 This Week. Is It Still Relevant Today?
Meant as a back-of-the-envelope calculation, it has gone on to become perhaps the second most famous equation in physics.
How does daylight saving time impact your health?
Sleep is impacted, as well as metabolism, mental health and vascular health.
Harry Houdini Died On Halloween 100 Years Ago. According To New Investigations By A Former Surgeon, No He Didn't.
The surgeon-turned-investigator noticed a few oddities in one of the death certificates. Have details of Houdini's death been changed?
Meta’s Muse Could Upend All Kinds of Businesses. It Hasn’t Yet
Companies have spent the past several weeks trying to reassure investors that Muse and other AI agents pose more of an opportunity than a threat.
Chornobyl's Genetically Unique Dogs Are Likely The Result Of Natural Selection, Not Radiation-Scrambled DNA
Wild dogs living near the remnants of the Chornobyl nuclear plant are genetically distinct, but the reason is a little more subtle than you might think.
How “Zombie Bacteria” Keep Making DNA Even When They’re Dead
Anyone looking for last-minute costume ideas for Halloween, we’ve got you sorted.
What’s in Your Vape Cart in 2026?
Recent studies showing heavy metal contamination in cannabis vape carts illustrate the need for additional testing and regulatory guidelines.
Is Meta’s Muse the Start of the Business-to-Agent Era?
Consumer AI agents are here, and they carry an understanding of the user that no brand app can match. Businesses need to be ready to serve agents as customers.
Two Dans, three Bobs: Alaska Senate controversy evokes 2024 WA fiasco
In Washington, the same-name scenario played out in 2024 when three-term Attorney General Bob Ferguson entered as the odds-on favorite in the race for governor.
How Can Science Better Support Interdisciplinary Researchers?
Academics and industry experts discuss how science can better support interdisciplinary researchers through reforming funding applications, collaboration, and traditional career advancement.
Local Politicians Are Thinking Twice About Serving
A Princeton study finds widespread hostility toward local officials in what one mayor calls “the age of rage”
New metabolic score may help predict healthy aging and disease risk
Studies conducted in various countries indicate that approximately 60% of people over the age of 65 currently live with two or more chronic conditions simultaneously.
I analyzed 1,133 Instagram posts with Meta’s new AI
Meta Muse for Small Business connects to your Instagram analytics. Here are five prompts to analyze your past posts before asking AI to create more.
UDE students develop wearable sensor patch for noninvasive health tracking
Having blood drawn, sending samples to a lab, waiting for results: Monitoring metabolic health often involves time-consuming tests.
NASA’s TSIS-2 Mission Aces Vacuum, Vibration Testing
The bright white lights reflect off the metallic hardware of a satellite poised for inspection. Engineers outfitted with bunny suits traverse the clean room,
ADOCIA Reports Third Quarter 2026 Financial Results and Provides a Business Update
LYON, France, October 29, 2026--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of metabolic diseases including diabetes and obesity, reports financial results for the third quarter of 2026 and provides a business update.
New orca tracking bracelets support FIU research
FIU and Fahlo have teamed up once again with the release of the new orca killer whale bracelets featuring the company’s first-ever hand-painted charm.
Holding Science to a Gold Standard Will Hold It Back
A metascientist pushes back against the unified and idealized vision of science embodied in NSF’s new Office of Metascience.
Tony Berlant dead: Artist known for metal collages, Kate Berlant's dad
Tony Berlant, a seminal influence in the West Coast Pop Art movement of the 1960s who was known as a 'painterly collage artist' with a penchant for working with tin, has died. He was 85.
Italian businesses believe businesses that fail to adopt AI risk falling behind competitors, want practical support to use AI
Findings of an Ipsos poll of 500 small- and medium-sized Italian business owners and employees
Surprise: The Google Xreal glasses debut at a Meta-beating $1,099
A price drop before launch? In this economy?
Cheraw recycling business shut down after stolen railroad materials, wiring found
Authorities ordered Cheraw Iron and Metal, Inc. to temporarily close on Tuesday after law enforcement executed a search warrant at 179 Legion Lane in Cheraw, recovering thousands of pounds of stolen r...
Rare Nanotyrannus Jodi Joins Dinosaurs "Lost To Science" Following $47.3 Million Auction Sale To Private Collector
“Reputable scientific journals will not publish research carried out on privately owned specimens. They are lost to science.”
Meta says it’ll probably delay its controversial new business terms again
Meta says conversations with partners could extend beyond November 20th.
Climate Change Is A Global Health Emergency And We’re Not Doing Enough About It, Major Report Warns
An international committee of experts has released new data on the accelerating threat climate change is posing to our health.
Meta has a new AI pet app called Waddle World
Meta has launched a new app called Waddle World, which essentially looks like a Tamagotchi clone, but with AI.
Modern Warfare 4's Missing Xbox Metacritic Score Sparks Change
The new shooter still barely has any critic reviews on Xbox
I Am Deeply Offended By Human Reproduction And I Think Aphids Have The Better System
Aphids took “Attack of the Clones” far too literally, with live clones, pre-loaded grandkids, optional wings, and sex only when absolutely necessary.
How does daylight saving time impact your health?
Sleep is impacted, as well as metabolism, mental health and vascular health.
Human Evolution and Disease: How Ancient DNA Shapes Modern Health Risks
Ancient DNA and evolutionary medicine help explain how inherited genetic variants interact with changing environments to influence modern disease risk. Neanderthal ancestry, metabolic variation, and evolutionary trade-offs provide insights into immunity, obesity, type 2 diabetes, and aging.
Men with lower testosterone at 31 reported good health 15 years later
Researchers analyzed testosterone concentrations measured at age 31 in 2,691 Finnish men and assessed self-reported health, medical conditions, and quality of life at age 46. Men across testosterone quartiles generally reported good health and excellent quality of life, while differences in metabolic and gastrointestinal conditions lost statistical significance after adjustment for waist circumference.
Animals Starves while the Kardashians Miss the Charts Again
(Welcome to my weekly streaming ratings report, the single best guide to what’s popular in streaming TV and what isn’t. I’m the Entertainment Strategy Guy, a former streaming executive who now analyzes business strategy in the entertainment industry. If you were forwarded this email, please subscribe to get these insights each week.) Before we get going, I’d like to offer congratulations to Jonathan Funke, whose suggestion “midflicks” won the poll for what I should call straight-to-streaming films which aren’t big or cinematic enough to go to theaters but seem too expensive for a TV movie. It’s so useful a term, I just used it last week! Now I just need to add this term to my data dictionary! Okay, on to this week’s issue. We’re starting out looking at Netflix/Ben Affleck’s latest crime thriller, Animals. I’ll also look at Disclosure Day heading to Peacock (it did better than you’d remember in theaters...) and a new movie based on toys. Plus, a long-time streaming flop returns for its eighth season...will it finally chart? (No.) Will anyone at Disney care? Probably not. All that, plus another look at new shows landing on streaming on 1-Oct from Reelgood, what streamer hasn’t had a film make the Luminate charts since August, Reacher’s long run on the charts, M_onster: The Lizzie Borden Story’s_ short run, the top shows in 2026 according to Samba TV, all the flops, bombs and misses, and a whole lot more. And I mean that last part: putting this week’s issue together, I assembled OVER 25 images, most of which are bespoke looks I made just for this report. Really, publishing articles like this takes the work of writing two articles: one is the narrative and the other is making charts/graphs. Let’s dive right in! (Reminder: The streaming ratings report focuses on the U.S. market and compiles data from Nielsen’s weekly top ten viewership ranks, Luminate’s Top Ten Data, JustWatch and Reelgood interest data, Samba TV household viewership, company datecdotes, Netflix hours viewed data, Google Trends, and IMDb to determine the most popular content. While most data points are current, Nielsen’s data covers the week of October 5th to October 11th, 2026. You can find a link to my terminology here.) Subscribe Film - Netflix’s Latest Star-Studded Thriller Goes For Glory The tempting angle for anyone writing about streaming film this month, like yours truly, is to ask, “Is this why Dan Lin lost his job at Netflix?” Take Animals, the Ben Affleck-starring-and-directing, Artists Equity-produced crime thriller that opened on 9-Oct. (Kerry Washington and Gillian Anderson are also in it.) If it did really well, then one could argue that Lin has another success on his resume. If it underperformed, then it’s another example of a Netflix underperformance this year. So where did Animals fall? Kinda in the middle, but that means it’s more “not a hit” than “big hit”. On Nielsen, it opened to 12.0 million hours, and here’s how that stacks up for 2026 films so far this year: Obviously, that’s not great. It’s both under my 15 million opening bar for “fine” for a Netflix film and 20 million bar for “great” opening. It did a bit better on Samba TV, getting to first place. That’s very, very good, though again, looking at the Nielsen data, it probably means that it was a light week overall. Luminate’s data is a bit closer to Samba TV’s, tied for 17th all time for single weeks since May of 2024: To top it off, no one seemed to like it. It has a 33 on Metacritic and only a 5.7 on IMDb. Both of these numbers could have been impacted by the stories about Affleck’s comments about using AI to make the film. Given the controversy, the film might not have been as bad as the ratings suggest, but it’s also not a bullish sign. All to say…yeah, on net this film isn’t a point in Dan Lin’s favor. At this point, Netflix’s slide has been long enough—going on since February—that I’m almost tempted to lower the bar for what a “hit” is on streaming. Post-February of 2026 or so, it seems like straight-to-streaming films just haven’t hit the same heights as they did from 2022 to 2025. Before we head onto the “Quick Hits” for film, I want to shout out a fellow newsletter whose articles I’ve been loving this year, LA Material, a new LA-based news outlet. For just a highlight of my favorite articles since July... I loved this article on Ghost Town, a group on Venice that clears homeless encampments. As a Los Angeleno, obviously I adore their articles on LA parking issues. Their article on illegal parking tickets got the City Council to address the issue! Also check out their article on people parking in medians. Check out their deep dive on what went wrong with the LA Jazz Festival and how it fell apart, or what’s wrong with USC’s finances. Finally, they wrote up a voter guide on voter guides for the LA General Election. So meta! In search of a city? L.A. Material is an independent news outlet covering the people, politics, culture and glorious chaos shaping Los Angeles. L.A. Material brings you intel on the city you can’t get anywhere else. From exploring how Reddit short stories became Hollywood’s hottest commodity to reporting on the survival jobs keeping entertainment workers afloat. And answering, once and for all, why the AMC Burbank escalator is always broken. Through their newsletters, podcast, videos, events, and member community, L.A. Material is designed to help Angelenos connect to Los Angeles and each other. Sign up now for the free weekday newsletter. Quick Notes on Film Steven Spielberg’s latest film, Disclosure Day, came to Peacock on 9-Oct, and I’ll admit that, after pulling its stats, I did a pinch of a double take. As I wrote throughout my deep, deep, deep dive on summer box office/Obsession/Backrooms/IP/superheroes, oftentimes the film media discusses films as “flops” or “misses” or “hits” without clarifying what they specifically mean. Since Disclosure Day didn’t make $250 million in the US or $500 million globally, it was definitely a disappointment by Spielbergian standards, who is the highest-grossing director of all time, and arguably even more ahead in adjusted grosses. But it did make $245 million globally on a $115 million budget, so it isn’t as big of a miss as I remember. That’s still probably not enough to break even in the theatrical window, when you factor in marketing costs…but it’s close. And it grossed a lot more even in the US than some titles with about ten times more coverage. Anyways, lots of preamble to say this one only did 4.5 million hours according to Nielsen, so it did make the charts, but on the low end. Here’s how it stacks up to other Peacock titles: Apple TV (née +) followed up their “success for them” Mayday with Matchbox The Movie. This one doesn’t look like a success even for them, but at least it’s not a miss. Apple/Skydance clearly tried to take advantage of the success of Barbie at the box office—let’s greenlight all the toy properties!!!—but of course, this didn’t make it to theaters. And it stars John Cena, who, as I argued earlier this summer, NEEDS to get his movies back in theaters. Anyways, this one has mixed-to-bad numbers. It missed the Samba TV and Nielsen charts in its first week, but did make Luminate with 7.1 million hours. That’s just enough to not be an outright miss, and about half what Mayday did earlier this summer. Speaking of Apple Studio’s Mayday, it ended up lasting five weeks on Luminate, which isn’t bad for Apple TV. On Nielsen, it had a three-week run, racking up 13.5 million hours total. Again, like Matchbox, the issue is the budget; I doubt that this viewership earned enough to justify that budget. Also, to be clear, neither of these films are “midflicks”; both should have gone to theaters. Toy Story 5 is not hanging around on the streaming charts on Disney+, so it’s not as leggy as either Zootopia 2 or Moana 2, and definitely not in the same class as Encanto. (It did make all the money at the box office, so Disney is going to be fine…) The Breadwinner on Netflix (from Sony) is down to 3.9 million hours in its third week. It only lasted for one week on the Samba TV charts. Netflix’s Doing Life had a smaller-than-normal binge release curve bounce, only going to 7.1 million hours from 6.0 to start, but it made Samba TV at fifth place in its second week. The Netflix documentary, The Widower: Til’ Death Do Us Part, also had a small binge release curve bounce to 6.5 million hours, but did make a second week on Samba TV. Meanwhile, Netflix’s Unabomber fell off after two weeks on Nielsen—which is not great at all—and Demon Slayer fell off after just one week. Over on Luminate, the two smaller titles The Swan: Behind the Mirror and Kill. Bury. Print both fell out of the Luminate top ten charts. The story of library film at the first of the month is the arrival of the Ice Age films on Netflix. Now, here’s a small example of optimizing your library that even Netflix could do better. Say you want to rent/license a new film series from Disney**.** A streamer could pay a big paycheck and then drop each Ice Age film on the exact same day of the month, the fourth of October. That’s one choice. In contrast, the streamer could have released each film one week apart, and make each one a mini-event for folks watching Ice Age films. Or even roll them out monthly. Netflix opted for the former strategy, and as a result, only three of the films made the Nielsen charts this week. The “Miss of the Week” goes to Tubi’s YA-ish horror film_, R.L. Stine’s Pumpkinhead 2_, which didn’t even make the Luminate charts like Tubi films usually do, or, should I say, “used to”? Tubi films, most of which are straight-to-streaming, used to reliably make the Luminate film charts (which only covers straight-to-streaming films), but a Tubi film hasn’t made it since August. The first Pumpkinhead got 1.4 million hours last year according to Luminate. As I wrote about this film before, it seems to be a bit muddled in terms of age: too scary for young kids but probably not scary enough for older kids. Speaking of Luminate, Netflix’s latest doc about a comic (expect more docs about comedians all month), Who Is Martin Mull?, flopped, getting just 200K and 700K hours according to Luminate. Three other film/special misses belonged to Hulu, including a standup special, Jamie Foxx: Take Care of Yourself, Neon’s latest horror film, Hokum, which made $17 million in the US, and a Family Guy Halloween special. (That last one was only 22 minutes, so it’s not a surprise it missed.) Finally, another Netflix standup special missed the charts, Mojo Brookzz: I Know You Lying missed too. I can confirm last week’s misses, most notably Paramount+’s Jackass: Best and Last, MUBI’s Teenage Sex and Death at Camp Miasma and HBO Max’s Evil Dead Burn. Television - I Can’t Visualize Nothing: The Kardashians Story Normally, in the mini-dive essays that open the Streaming Ratings Report, I focus on shows that do well or, at the very least, make the charts. Why? Because as I’ve said time and again, I can’t visualize nothing like, say, the Kardashians’ TV shows. Here’s the TV debuts chart for this week with a missing spot for The Kardashians, whose eighth season just landed on Hulu:
Watch the newest commercials from Ninja, Meta Muse, AT&T Business and more
Ninja shows off its HydraSense Intelligent Water Filtration System in a spot starring Tom Brady.
Call of Duty’s Metacritic celebration highlights a bizarre Xbox problem — nobody is reviewing games on Xbox
Microsoft's cumbersome review system is hurting its own platform.
High metal exposures after wildfires may affect lung function
After the Maui wildfires, researchers found a link between participants exposed to higher levels of metal mixtures and worse lung function.
Nvidia, AMD Get Their Jollies Hooking Up With Meta's Muse
Nvidia and AMD separately announced deals with Meta Platforms to power the social media company's AI endeavors. Nvidia stock rose.
Exclusive: Meta director Rohit Patel departs after 8 years to take on Microsoft Office Suite
Rohit Patel is departing Meta after eight years working on AI evaluations and reinforcement learning, TechCrunch has exclusively learned. His startup, Ndoc, aims to take on Microsoft Office Suite.
Why are Meta and TikTok censoring women’s health content?
OPINION: Thanks to the way their algorithms work, censorship or suppression of women’s healthcare information on social media networks is the norm.
Giving quantum computers a way to pick up where they left off
FIU is researching how to restart quantum workflows after interruptions to preserve computational progress. It lays the groundwork for quantum machine learning for drug discovery and climate modeling.
John Goblikon wants to fire his ghostwriter. The problem? He is his ghostwriter
Comedian Dave Rispoli created John Goblikon, a metal-loving goblin who has become a comedy star with a personality all his own.
I Tested Every Major AI Agent for a Day. Here’s the Best One
I ranked six AI agents—from Meta’s Muse to Anthropic’s Claude Duet—on how well they completed basic tasks.
Vice President holds rally at Kansas born business
United States Vice President JD Vance visits Haas Metal Engineering Inc. ahead of midterm election.
Moving past outdated models: a seminar exploring religion and public health
Editors of the Handbook on Religion and Health: Pathways for a Turbulent Future Gary Gunderson and Teresa Cutts (“TC”), visited the Bloomberg School of Public Health on Thursday, Oct. 22 to give their talk “Watersheds: Moving beyond Downstream/Upstream Metaphors to Advance Public Health.”
The vaginal microbiome may relate to more than reproductive health
Researchers analyzed vaginal microbiota, metabolites, and psychological questionnaire scores in 105 young Italian women and found associations between microbial community types and reward responsiveness, motivational drive, and behavioral inhibition. Exploratory models identified statistical links involving vaginal GABA and valine, but the cross-sectional study could not establish whether microbiome changes influence psychological functioning or the reverse.
iPhone AI Images and Edits Now Have a Hidden Watermark
Images generated with Image Playground and some photos edited with Apple Intelligence will now include a SynthID watermark. Apple announced plans to add SynthID support back in June, and the feature is live in iOS 27.2. SynthID is a Google-created tool that identifies AI-generated content. It watermarks images and videos at the pixel level instead of adding metadata. Google says it does not affect image quality and is meant to survive cropping, filters, and compression.
MSG Entertainment Paid New Legal Chief $2.6M in First Three Months
Allen Lo, the former Meta deputy general counsel, took over as MSG Entertainment's chief legal officer in March, months before the company was hit with litigation over a massive data breach and launched a defamation suit against Wired.
Meta Plans To Raise Up To $95 Billion In Equity To Power AI
Meta stock was lower premarket after the tech giant announced plans to raise $95 billion in equity.
One Radio Source In Our Galaxy Has Been Producing Signals For At Least 20 Years That No One Can Explain
Still not aliens, but one of the weirdest things we have found in a sky where weird things are not in short supply.
Meta looks to raise up to $95 billion from stock sales for AI build out
Meta is seeking more cash as it spends heavily on AI infrastructure, data centers, and computing power as it develops consumer AI products.
How to Manage Symptoms of Heart Failure
(Feature Impact) Americans are facing a growing health challenge, with 1 in 4 adults at risk of heart failure, according to the Heart Failure Society of America. Additionally, approximately 6.7 million U.S. adults who are 20 years old or older are currently living with heart failure, and that number is projected to reach 8.7 million by 2030. googletag.cmd.push(function() { googletag.display('JGFI_Article_300x250'); }); Managing heart failure is a significant expense to the U.S. healthcare system, costing the nation approximately $40 billion in 2020 and expected to increase to approximately $142 billion a year by 2050.If you (or a loved one) are living with the condition, consider these tips to help manage it.Adhere to the Treatment and Follow-Up PlanOngoing outpatient care is important when managing heart failure. Understand the treatment plan provided by your healthcare team, make diet and lifestyle changes, take medications as directed and keep recommended follow-up appointments.Pay attention to changes in symptoms and communicate with your healthcare provider if treatment does not seem to be working as expected. If their conditions are left unmanaged, patients can experience a range of heart-failure-related symptoms such as shortness of breath, fatigue, buildup of fluid and more.Understand Challenges with Diuretic TreatmentDiuretics help the body remove excess fluid and are commonly used to treat swelling, or edema, associated with heart failure. Your provider may try different diuretics, sometimes referred to as “water pills,” to manage your heart failure symptoms. However, intravenous (IV) diuretic therapy may be required for some patients if symptoms continue.Ask About Treatment Options Before IV Care Is NeededFor some adults, a healthcare provider may consider recommending an at-home, non-oral diuretic option prior to escalating to IV therapy.For example, ENBUMYST™ (bumetanide nasal spray) is a prescription diuretic used in adults to treat edema associated with congestive heart failure. It’s administered as a nasal spray for short-term use to manage excess fluid with the goal of transitioning to oral diuretic therapy when appropriate.Talk with your healthcare provider to learn more and visit enbumyst.com. Read the full Prescribing Information and Patient Information.Photo courtesy of Shutterstock googletag.cmd.push(function() { googletag.display('JGFI_Article2_300x250'); }); Important Safety InformationWhat is ENBUMYST?ENBUMYST is a prescription medicine used in adults to treat swelling caused by excess fluid in the body (edema) from congestive heart failure, liver disease, and kidney disease.What is the most important information I should know about ENBUMYST?ENBUMYST is a diuretic that helps your body remove fluid. Losing too much fluid can cause dehydration, low blood volume, and increase the risk of blood clots. Blood abnormalities may include decreased salts (electrolytes), and increased nitrogen, glucose and uric acid. The risk of these abnormalities is higher in elderly people, those using higher doses, or those who do not get enough electrolytes by mouth.You should not use ENBUMYST if you have severe electrolyte loss. Tell your healthcare provider if you experience unusual thirst; dizziness or lightheadedness; weakness or tiredness; fast heart rate; dry mouth or tongue; sudden pain; redness or swelling in your joints; pain, swelling, redness, or warmth in your leg; shortness of breath or fast breathing; high blood sugar; dark urine; pale, tight, cool or clammy skin; muscle cramps; confusion.Do not use ENBUMYST if you have low or no urine production or are allergic to bumetanide or to any of the ingredients in ENBUMYST.Before using ENBUMYST, tell your healthcare provider if you have low electrolytes, are on a low-salt diet, have diarrhea, diabetes, nasal problems such as a runny or stuffy nose or polyps, a history of nasal injury or surgery, are or plan to become pregnant, are or plan to breastfeed.Tell your healthcare provider about all the medicines you take, including prescriptions, over-the-counter medicines, vitamins, and herbal supplements.ENBUMYST may cause serious side effects, such as worsening kidney function and ringing in the ears or hearing loss.The most common side effects of ENBUMYST include dehydration, headache, muscle cramps, dizziness, low blood pressure, nausea, and abnormal brain functioning with certain liver problems.These are not all the possible side effects of ENBUMYST. Talk to your healthcare provider for more information.Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.US-ENBU-2600110 googletag.cmd.push(function() { googletag.display('JGFI_Article3_300x250'); });
ESMO: Roche touts ‘convincing’ phase 3 KRAS data after win over rivals
Roche has shed more light on its investigational KRAS G12C inhibitor's phase 3 victory over Amgen’s Lumakras and Bristol Myers Squibb’s Krazati. The open-label Krascendo 1 trial enrolled 338 people with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC). Patients who had already received a KRAS G12C inhibitor or pan-KRAS/RAS inhibitor were excluded from the trial. Participants received either divarasib once daily, Lumakras once daily or Krazati twice daily. Roche announced back in July that divarasib had demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS), meeting the trial’s primary and key secondary endpoints. But the Swiss pharma had been holding back the detailed data until now. At the European Society for Medical Oncology (ESMO) Congress in Madrid, Roche revealed that median OS for the 167 patients who received divarasib was 17.7 months, compared to 12 months for the 171 patients who received Lumakras or Krazati. The benefit was similarly clear when it came to median PFS, which stood at 9.8 months versus 5.7 months, respectively. A total of 44% of patients receiving divarasib were alive without disease progression at one year, compared to 24% of the control group, according to Roche’s presentation. It was a similar story for the objective response rate, which came in at 58% for divarasib versus 32% for the control group, while median duration of response was 11.9 months versus 6.9 months. Stefan Frings, M.D., Ph.D., deputy chief medical officer at Roche Pharma, told Fierce that the data made for a “very comprehensive, strong package, which should be convincing to health authorities.” “It’s an important advance for patients with lung cancer,” Frings said in an interview at a Madrid hotel during the conference. “It's a second-line setting, and patients who receive divarasib benefit compared to the current first-generation KRAS G12C inhibitors by having far longer overall survival,” he continued. “They live longer. They have better progression-free survival, better response rates, and with a safety profile which is—if [anything]—even better,” he said. According to Roche, 4.8% of patients receiving divarasib discontinued treatment due to treatment-related adverse events, compared to 11.7% in the control group. Serious treatment-related adverse events were also less common with divarasib, at 7.8% versus 15.2%. Roche’s confidence in divarasib had been building even before this phase 3 success. The candidate had already shown better potency and selectivity than the incumbent KRAS G12C inhibitors Krazati and Lumakras in preclinical tests. After cross-trial comparisons suggested that the edge translated into better clinical outcomes, Roche axed a study comparing divarasib to the chemotherapy docetaxel and went toe-to-toe with Lumakras and Krazati. “We designed the drug on purpose with higher potency and better selectivity,” Frings explained. “So, based on preclinical models, we clearly knew it would be superior to the first generation.” “It’s honestly not so frequent that pharma companies go head-to-head,” he added. “But if you want to make a point, if you want to convince payers, prescribers and patients … then a head-to-head win is rather rewarding.” While Amgen and BMS reached the regulatory finish line first for KRAS G12C-mutated, locally advanced or metastatic NSCLC in 2021 and 2022, respectively, they have struggled to capitalize on their head start. Krazati brought in $55 million for BMS in the second quarter, while Lumakras delivered $111 million to Amgen. For its part, Roche is aiming for peak divarasib sales of 1 billion to 2 billion Swiss francs ($1.2 billion to $2.5 billion), according to Frings. The Big Pharma is currently recruiting patients into a phase 3 trial comparing divarasib plus Keytruda against Keytruda plus chemotherapy in previously untreated advanced or metastatic nonsquamous KRAS G12C-mutated NSCLC. Roche has previously suggested that sales in metastatic disease would account for most of the forecast. Frings was tight-lipped on the exact timeline for a regulatory filing but said the Swiss pharma is “certainly keen to get this to as many patients as possible around the world.” Roche has more RAS drugs coming up behind divarasib. The pharma has already launched phase 1 trials of a pan-RAS inhibitor called RG6505 and a KRAS G12D inhibitor dubbed RG6620 in solid tumors. Roche’s partner Chugai Pharmaceutical is also testing a pan-KRAS inhibitor called AUBE00. Roche has made a “deliberate effort” to test a range of RAS drugs, Frings said. “If you have many rare mutations and you are scrambling to find sufficient patients, a pan-RAS inhibitor makes a lot of sense,” he explained.
New Instagam app on Apple TV brings reels, long-form video and live shows
Meta just made it easier to doomscroll from the comfort of your couch.
When a teen posts a selfie, how much filter is 'too much' filter?
The recent Meta settlement includes a clause banning "cosmetic procedure filters" for teens. But defining what constitutes an extreme makeover isn't easy.
Physicists Hold A Positron Captive For Months, Odd Correlation Found In Reincarnation Reports, And Much More This Week
All the biggest science news stories of the week.
AI image generator test: Canva Craft vs. ChatGPT, Gemini, Meta Muse
While Canva's new image generation tool fell short at making a birthday card, it's catching up to more powerful models in creating realistic images.
The connection between diabetes, cardio-kidney-metabolic health
University Health specialists will discuss how heart, kidney and metabolic conditions are connected and how coordinated care can help at the next KSAT Community Town Hall
Senator says planned Meta commercial terms update could harm US businesses
WASHINGTON, Oct 23 (Reuters) - US Senator Marsha Blackburn, a Tennessee Republican, on Friday raised concerns about Facebook parent Meta Platforms' plan to update its commercial terms, saying it coul...
Political ads on Facebook, after the Meta ban
Since 6 October 2025, Meta has no longer allowed paid advertising on political, electoral or social matters in the European Union. The company decided in response to Regulation (EU) 2024 / 900 on transparency and targeting political advertising (TTPA), applicable from 10 October 2025, the requirements of which it considers "impossible to apply '[1, 2].
Meta delays new business terms after publisher pushback on AI scraping
Legal experts argued that Meta’s changes weren’t enough to rule out AI scraping.
Commissioner Lahbib visits Ottawa for discussions on preparedness for health emergencies
Commissioner for Equality, Preparedness and Crisis Management, Hadja Lahbib will visit Ottawa to meet with Canadian authorities to discuss health emergencies preparedness and response. The trip includes a visit to an aircraft factory where a total of 24 firefighting aircraft are being produced.
Goldman Sachs CEO David Solomon on AI’s economic impact: ‘There’s very little that we do where we need frontier models’
"The important thing is to get it right, not to get it quicker," Solomon told small businesses of his $500 million AI push with OpenAI, Anthropic, Google and Meta.
Sixth in Kona: Sam Long's Performance and the Science Behind the Build
How metabolic testing helped inform the training, pacing, and fueling decisions behind a sixth-place Ironman World Championship finish.
Three Of The Earth’s Five Mass Extinctions May Not Have Been What We Thought
While more gradual processes may reduce how dramatic these events look in hindsight, it also makes human-induced extinction stick out more severely.
Bridging Climate Science and Cardiometabolic Health from Radiative Forcing to Disease Risk
Cardiovascular disease remains a dominant cause of global morbidity and mortality, yet conventional prevention...
Postpartum recovery may influence long-term maternal aging and health
Jesse Poganik, PhD, of the Division of Genetics within the Department of Medicine at Mass General Brigham, is the senior author of a paper published in Trends in Endocrinology & Metabolism, "The Postpartum Recovery Window as a Determinant of Maternal Aging." Stephen Albright, formerly of Mass General Brigham, is the lead author.
Meta's board thinks keeping Zuckerberg at its California office is key
The tech giant's effort to dissuade its CEO from relocating reflects a common belief that the best work happens when everyone is together in person.
Pedal to the Metal: NASA’s Psyche Heads Toward Asteroid Belt
With a successful Mars gravity assist in its rearview mirror, NASA’s Psyche spacecraft has fired up its thrusters and is accelerating to the metal-rich
Goldman Sachs spends big to give small businesses an AI boost
The Wall Street giant is committing $500 million to expand its 10,000 Small Businesses program and launch an AI institute, partnering with Google, Meta, OpenAI and Anthropic to bring AI know-how to Main Street. NBC's Christine Romans spoke exclusively with Goldman Sachs CEO David Solomon and with small businesses figuring out how to make AI work for them.
How To Tame An Antimatter Particle: Physicists Hold A Positron Captive For Months
It might not sound like a big deal until you remember what happens when antimatter meets matter.
How a Legal Backlash Against Big Tech Is Forcing Big Changes
A series of lawsuits has created a new de facto regulatory regime as courts order companies like Meta and Google to change their business practices — and pay up.
How Systems Biology Is Adopting an Engineering Framework
Everything from metabolic pathways optimized for efficiency to brain blood vessels designed as protective shock absorbers demonstrates multi-level planning.